Prof. Dr. Julio César Fernández Travieso, National Centre for Scientific Research, Cuba
Prof. Dr. Julio César Fernández Travieso is a distinguished Cuban pharmaceutical scientist and Head of the Clinical Trials Unit at the National Centre for Scientific Research in Havana. He earned his BSc in Pharmaceutical Sciences in 1996 and completed his PhD in 2003. As a Senior Researcher and Full Academician of the Cuban Academy of Sciences, he has made significant contributions to the clinical development of natural-origin pharmaceuticals. With over 150 scientific publications and more than 120 conference presentations, his work has had a wide-reaching impact on experimental pharmacology and clinical research in Cuba.
Publication Profile
Scopus
Orcid
🎓 Education
Prof. Dr. Fernández Travieso completed his Bachelor of Science in Pharmaceutical Sciences from Havana University in 1996. He pursued advanced academic training and was awarded a PhD in Pharmaceutical Sciences in 2003. His education provided a comprehensive foundation in experimental pharmacology, pharmaceutical formulation, and clinical research methodologies. These qualifications enabled him to lead major clinical studies and serve in senior research roles. His academic background is firmly rooted in the development of therapeutics derived from natural sources, particularly those innovated in Cuba.
💼 Experience
Dr. Julio César Fernández Travieso currently serves as the Head of the Clinical Trials Unit at the National Centre for Scientific Research, Havana. With a career spanning over two decades, he has led multiple Phase I–IV clinical trials for novel therapeutics developed in Cuba. He is a Senior Investigator specializing in Clinical Pharmacology and has contributed to drug development, safety monitoring, and pharmacodynamic studies. His leadership has enabled the translation of research into approved therapeutic products. He also holds the title of Full Academician of the Cuban Academy of Sciences.
🏅 Awards and Honors
Prof. Dr. Fernández Travieso has received numerous national and international recognitions for his work in pharmaceutical sciences and clinical research. Several of his more than 120 scientific presentations have earned awards at global conferences. His appointment as a Full Academician of the Cuban Academy of Sciences highlights his standing in the scientific community. These honors reflect his role in advancing Cuba’s pharmaceutical innovation, particularly in clinical evaluation and development of natural products. His contributions have positioned him as a scientific leader in Latin America’s biomedical research landscape.
🔍 Research Focus
Dr. Fernández Travieso’s primary research interest lies in experimental pharmacology and conducting Phase I–IV clinical trials of natural-origin pharmaceuticals. He has played a pivotal role in evaluating and validating Cuban-developed products such as Policosanol, Abexol, Prevenox, Vasoactol, and Palmex. His work bridges laboratory pharmacology and clinical application, ensuring rigorous scientific evidence supports therapeutic claims. His research addresses chronic conditions like cardiovascular and metabolic disorders using innovative natural compounds. He also explores drug safety, efficacy, and pharmacokinetics in human populations.
Publication Top Notes
-
Efficacy and Safety of Policosanol (Sugarcane Wax Alcohols) 20 mg/Day in Cuban Prehypertensive Patients: A Randomized, Double-Blind, Multicentre Study 🧑⚕️, 2025
-
Comparative Study of the Efficacy and Safety of the Ozonated Sunflower Oil, Ketoconazole and Terbinafine in Patients with Dermatophytosis 💊, 2024
-
Beeswax Alcohol Prevents Low-Density Lipoprotein Oxidation and Demonstrates Antioxidant Activities in Zebrafish Embryos and Human Subjects: A Clinical Study 🧬, Cited by: 6, 2024
-
Effects of Policosanol in Patients with Metabolic Syndrome: A Six-Month Study 💉, Cited by: 6, 2020
-
Efficacy and Tolerability of Roystonea Regia Lipid Extract (D-004) and Terazosin in Men with Symptomatic Benign Prostatic Hyperplasia: A 6-Month Study 🔬, Cited by: 7, 2019
-
Concomitant Use of Policosanol and Antiplatelet Drugs in Older Patients 💊, 2019
-
Non-Cardioembolic Ischemic Stroke Hypertensive Patients, A Therapeutic Hope. Reply 🧠, 2019